Inactivation of other PRC2 components equivalent to EZH2 loss has also been observed in MPN and MDS/MPN patients, e.g., in the form of loss-of-function mutations of SUZ12 and EED [31,32]. This evidence concerns the gene SUZ12 and myeloproliferative neoplasm.